Supported by Crohn's and Colitis Foundation of America, the Harry B. and Leona Helmsley Charitable Trust, and National Institutes of Health (NIH) RC1DK086242.
Basic Science Review
You have free access to this content
Healing of intestinal inflammation by IL-22†
Article first published online: 22 FEB 2012
DOI: 10.1002/ibd.22929
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Additional Information
How to Cite
Mizoguchi, A. (2012), Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis, 18: 1777–1784. doi: 10.1002/ibd.22929
- †
Publication History
- Issue published online: 9 AUG 2012
- Article first published online: 22 FEB 2012
- Manuscript Accepted: 1 FEB 2012
- Manuscript Received: 13 JAN 2012
REFERENCES
- 1, , . Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000; 164: 1814–1819.
- 2, . IL-22: a two-headed cytokine in IBD? Inflamm Bowel Dis. 2009; 15: 473–474.
- 3, , , et al. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 2010; 21: 365–379.
- 4, . Recent advances in IL-22 biology. Int Immunol. 2011; 23: 159–163.
- 5, , , et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29: 71–109.
- 6, , . Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011; 12: 383–390.
- 7, , , et al. IL-22 increases the innate immunity of tissues. Immunity. 2004; 21: 241–254.
- 8, , , et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005; 129: 969–984.
- 9, , , et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008; 118: 534–544.
- 10, , , et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 2008; 29: 947–957.
- 11, , , et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol. 2009; 10: 83–91.
- 12, , , et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009; 457: 722–725.
- 13, , , et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity. 2007; 27: 647–659.
- 14, , , et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007; 445: 648–651.
- 15, , , , et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008; 118: 597–607.
- 16, , . Interleukin-22: a sheep in wolf's clothing. Nat Med. 2008; 14: 247–249.
- 17, . Animal models of IBD: linkage to human disease. Curr Opin Pharmacol. 2010; 10: 578–587.
- 18, , , et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol. 2011; 13: 144–151.
- 19, , , et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G827–838.
- 20, , , et al. Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. Lab Invest. 2010; 90: 496–505.
- 21, , , et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med. 2009; 206: 1465–1472.
- 22, , , et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis. 2008; 14: 204–212.
- 23, , . Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573–621.
- 24. Animal models of inflammatory bowel disease. Prog Mol Biol Transl Sci. 2012; 105: 263–320.
- 25, , , et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol. 2008; 181: 7420–7427.
- 26, , , et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009; 10: 857–863.
- 27, , , et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009; 10: 864–871.
- 28, , , et al. γδ T cells protect against lung fibrosis via IL-22. J Exp Med. 2010; 207: 2239–2253.
- 29, , , et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008; 14: 275–281.
- 30, , , et al. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity. 2010; 32: 803–814.
- 31, , , et al. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J Immunol. 2010; 185: 3913–3918.
- 32, . The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol. 2011; 12: 21–27.
- 33, , . Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol. 2009; 9: 229–234.
- 34, , , et al. Lineage relationship analysis of RORgammat+ innate lymphoid cells. Science. 2010; 330: 665–669.
- 35, , , et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med. 2009; 206: 3047–3059.
- 36, , , et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease. Gastroenterology. 2011; 141: 217–226.
- 37, , , et al. Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology. 2010; 139: 882–892.
- 38, , , et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011; 208: 1127–1133.
- 39, , , et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008; 14: 282–289.
- 40, , , et al. Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe. 2011; 10: 44–53.
- 41, , , et al. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity. 2011; 34: 122–134.
- 42, , , et al. Transcription factor c-Maf mediates the TGF-β-dependent suppression of IL-22 production in T(H)17 cells. Nat Immunol. 2011; 12: 1238–1245.
- 43, , , et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med. 2009; 206: 35–41.
- 44, , , et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008; 453: 106–109.
- 45, , , et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011; 141: 237–248.
- 46, , , et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012; 36: 92–104.
- 47, , , et al. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004; 22: 929–979.
- 48, , , et al. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol. 2004; 4: 679–691.
- 49, , , et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol. 2007; 178: 5973–5981.
- 50, , , et al. New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem. 2009; 284: 26377–26384.
- 51, , , et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 2011; 106: 1544–1555.
- 52, , , et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006; 36: 1309–1323.
- 53, , , et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006; 203: 2271–2279.
- 54, , , et al. Colonic epithelial functional phenotype varies with type and phase of experimental colitis. Gastroenterology. 2003; 125: 148–161.
- 55, , , et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006; 313: 1126–1130.
- 56, , , et al. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med. 2007; 204: 1891–1900.
- 57, , , et al. Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol. 2012; 5: 99–109.
- 58, , , et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol. 2011; 12: 1151–1158.
- 59, . Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008; 70: 431–457.
- 60, , , et al. ATP drives lamina propria T(H)17 cell differentiation. Nature. 2008; 455: 808–812.
- 61, , , et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009; 139: 485–498.
- 62, , , et al. The membrane-bound mucin Muc1 regulates Th17-cell responses and colitis in mice. Gastroenterology. 2011 [Epub ahead of print].
- 63, , , et al. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas. 2010; 39: 510–515.
- 64, , , et al. Transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol. 2007; 179: 735–739.
- 65, , , , et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J Exp Med. 2007; 204: 1417–1429.
- 66, , , et al. Glycosyltransferase function in core 2-type protein O glycosylation. Mol Cell Biol. 2009; 29: 3770–3782.
- 67, , , et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol. 2009; 183: 687–695.
- 68, , , et al. Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol. 2004; 24: 9390–9400.
- 69, , , et al. Activation of epithelial STAT3 regulates intestinal homeostasis. Cell Cycle. 2010; 9: 652–655.
- 70, , , et al. DMBT1 is a novel gene induced by IL-22 in ulcerative colitis. Inflamm Bowel Dis. 2011; 17: 1177–1188.
- 71, , , et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010; 52: 1291–1300.
- 72, , , et al. Interleukin-22 deficiency accelerates the rejection of full major histocompatibility complex-disparate heart allografts. Transplant Proc. 2008; 40: 1593–1597.
- 73, , , et al. Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol. 2006; 177: 3635–3643.
- 74, , , et al. High expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway inflammation via an IL-10-associated mechanism. J Immunol. 2011; 187: 5077–5089.
- 75, , , et al. IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis. J Immunol. 2011; 187: 2130–2139.
- 76, , , et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009; 60: 390–395.
- 77, , , et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011; 186: 1228–1239.
- 78, , , et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol. 2007; 179: 8098–8104.
- 79, , , et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol. 2009; 183: 6639–6645.
- 80, , , et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest. 2010; 120: 1762–1773.
- 81, , , et al. Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol. 2008; 181: 7891–7901.
- 82, , , et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. 2010; 3: 361–373.
- 83, , , et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2009; 136: 257–267.
- 84, , , et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med. 2011; 208: 1027–1040.
- 85, , , et al. A unique B-2 B cell subset in the intestine. J Exp Med. 2008; 205: 1357–1368.
- 86, , , et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med. 2009; 87: 523–536.
- 87, , , et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med. 2010; 207: 1293–1305.
- 88, , , et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A. 2001; 98: 9511–9516.
- 89, , , et al. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol. 2001; 166: 7090–7095.
- 90, , , et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol. 2001; 166: 7096–7103.
- 91, . Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066–2078.
- 92, , . Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474: 307–317.
- 93, , , et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361: 2033–2045.
- 94, , , et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009; 41: 216–220.
- 95, , , et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010; 42: 1118–1125.

1536-4844/asset/IBD_left.gif?v=1&s=9aca2b5041534c51cac4bb66560294c77a457a07)
1536-4844/asset/IBD_right.gif?v=1&s=402e3e241083497ae622916e85e47f64138255a4)
